Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$47.3 million.

  • Enanta Pharmaceuticals' Cash from Investing Activities fell 16864.43% to -$47.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$75.9 million, marking a year-over-year decrease of 15408.29%. This contributed to the annual value of $40.3 million for FY2025, which is 3071.69% down from last year.
  • Enanta Pharmaceuticals' Cash from Investing Activities amounted to -$47.3 million in Q4 2025, which was down 16864.43% from $2.3 million recorded in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Cash from Investing Activities peaked at $72.7 million during Q3 2021, and registered a low of -$145.7 million during Q2 2023.
  • Moreover, its 5-year median value for Cash from Investing Activities was $14.0 million (2022), whereas its average is $5.4 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Cash from Investing Activities soared by 280267.57% in 2021 and then crashed by 99856.97% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $45.5 million in 2021, then fell by 26.22% to $33.6 million in 2022, then tumbled by 139.07% to -$13.1 million in 2023, then soared by 625.3% to $68.9 million in 2024, then tumbled by 168.64% to -$47.3 million in 2025.
  • Its Cash from Investing Activities was -$47.3 million in Q4 2025, compared to $2.3 million in Q3 2025 and -$26.5 million in Q2 2025.